rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kathleen P. Gallagher

Director and Officer

Company insider

Files Form 4 as: Director and Officer, Atrium Therapeutics; Chief Program Officer, Avidity Biosciences.

Every Form 4 they filed

In numbers

Trades disclosed
55
Buys
0
Sells
9
Bought
$0
Sold
$1.2M
Companies
2
Companies where not an officer
0
First trade
6 Jan 2025
Last trade
18 Sep 2026
Last filed
22 Sep 2026

Companies traded

Where they are an officer
RNA Atrium TherapeuticsDirector, Officer · Biotechnology · last 18 Sep 20260 buys · 0 sells
Avidity BiosciencesOfficer · Biotechnology · last 27 Feb 20260 buys · 9 sells

Activity over time

1 Jan 2025 – 1 Oct 2026
20Jan 25Jun 25Dec 25May 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
18 Sep 2026filed 22 Sep 2026RNA Atrium TherapeuticsBiotechnologySEC FORM 4 Code F$104K11,632 at $8.95filing
18 Sep 2026filed 22 Sep 2026RNA Atrium TherapeuticsBiotechnologySEC FORM 4 Code F$104K11,632 at $8.95filing
20 Apr 2026filed 22 Apr 2026RNA Atrium TherapeuticsBiotechnologySEC FORM 4 Code A—102,500 at $0.00filing
20 Apr 2026filed 22 Apr 2026RNA Atrium Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—205,000 at $0.00filing
20 Apr 2026filed 22 Apr 2026RNA Atrium Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—205,000 at $0.00filing
20 Apr 2026filed 22 Apr 2026RNA Atrium TherapeuticsBiotechnologySEC FORM 4 Code A—102,500 at $0.00filing
27 Feb 2026filed 27 Feb 2026Avidity BiosciencesBiotechnologySEC FORM 4 Code D—80,303filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—22,321filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—13,829filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—22,321filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—13,829filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—9,244filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—13,352filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—27,584filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—42,480filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—13,520filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—16,000filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivativeSEC FORM 4 Code D—50,000filing
27 Feb 2026filed 27 Feb 2026Avidity Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—9,244filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed9

Buys in green, sells in red, by the company’s sector.

Related people

Steven George HughesChief Medical Officer · Chief Medical Officer at Atrium Therapeutics, filing Form 4 there in the last year
W. Michael FlanaganDirector · Director at Atrium Therapeutics, filing Form 4 there in the last year
Sarah BoyceDirector · Director at Atrium Therapeutics, filing Form 4 there in the last year
Brendan R. WinslowChief Financial Officer · Chief Financial Officer at Atrium Therapeutics, filing Form 4 there in the last year
Rocio Martin HoyosChief Strategy Officer · Chief Strategy Officer at Atrium Therapeutics, filing Form 4 there in the last year